Back to top
more

OncoCyte (OCX)

(Delayed Data from NSDQ)

$2.90 USD

2.90
21,566

-0.10 (-3.33%)

Updated Nov 4, 2024 03:52 PM ET

After-Market: $2.90 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 24.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 900% and 3.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Elevance Health (ELV) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of 2.16% and 2.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

3 Medical Services Stocks to Buy Amid Industry Challenges

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most. However, staffing shortages may disrupt the trend.

Life Time Group Holdings, Inc. (LTH) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Life Time Group Holdings, Inc. (LTH) delivered earnings and revenue surprises of 16.67% and 0.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Matches Q4 Earnings Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

OncoCyte (OCX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of 38.46% and 32.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for OncoCyte (OCX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Strength Seen in Cano Health, Inc. (CANO): Can Its 32.2% Jump Turn into More Strength?

by Zacks Equity Research

Cano Health, Inc. (CANO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why OncoCyte (OCX) Looks Ripe for Bottom Fishing

by Zacks Equity Research

OncoCyte (OCX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

OncoCyte (OCX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of 46.15% and 17.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -114.29% and 8.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sotera Health Company (SHC) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Sotera Health Company (SHC) delivered earnings and revenue surprises of 12.50% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Icon PLC (ICLR) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Icon PLC (ICLR) delivered earnings and revenue surprises of 2.51% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OncoCyte (OCX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of 15.38% and 16.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Tivity Health (TVTY) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Tivity Health (TVTY) delivered earnings and revenue surprises of -4.76% and 4.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Q4 Earnings Match Estimates, Revenues Lag (Revised)

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of 0% and -17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of -20% and 17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Tivity Health (TVTY) Lags Q4 Earnings Estimates

by Zacks Equity Research

Tivity Health (TVTY) delivered earnings and revenue surprises of -21.05% and 0.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LHC Group (LHCG) Q4 Earnings Lag Estimates

by Zacks Equity Research

LHC (LHCG) delivered earnings and revenue surprises of -4.55% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AMN Healthcare Services (AMN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare (AMN) delivered earnings and revenue surprises of 14.34% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of -57.14% and -69.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.